
- September 2019 Pain Management
- Volume 85
- Issue 9
Generic Products (September 2019)
Generic product news for September 2019
RAMELTEON TABLETSCOMPARE TO: Rozerem
Dr. Reddy's has launched its generic Rozerem in an 8-mg dosage strength indicated to treat insomnia. Frequent adverse effects include dizziness, drowsiness, and fatigue. The recommended dose of Ramelteon is 8 mg taken 30 minutes before going to bed and should not exceed 8 mg per day. The drug works by slowing down the nervous system, helping patients get to sleep faster and stay asleep.
DOSAGE FORM: Tablet
FOR MORE INFORMATION: drreddys.com
PREGABALIN CAPSULESCOMPARE TO: Lyrica
Amneal Pharmaceuticals recently received approval for and launched its generic version of Lyrica 25, 50, 75, 100, 150, 200, 225, and 300 mg. Pregabalin is indicated to treat neuropathic pain associated with diabetic peripheral neuropathy, fibromyalgia, postherpetic neuralgia, and spinal cord injury, as well as an adjunctive therapy to treat partial onset seizures in patients 17 years or older. Increased seizure frequency may occur if the drug is rapidly discontinued. The Amneal Pharmaceuticals FDA application was 1 of 9 approved in July for the first generics of Lyrica.
DOSAGE: Capsule
FOR MORE INFORMATION: amneal.com
ABIRATERONE ACETATE TABLETSCOMPARE TO: Zytiga
The FDA has approved MSN Labs' abiterone acetate 250-mg tablets to treat prostate cancer when used with a steroid medication (methylprednisolone or prednisone). The tablets are available in 120-count bottles to treat men with metastatic castration-resistant prostate cancer. Possible adverse effects include cough, headache, hot flush, hypertension, upper respiratory tract infection, and urinary tract infection.
DOSAGE: Tablet
FOR MORE INFORMATION: msnlabs.com
ERYTHROMYCIN DELAYED-RELEASE TABLETSCOMPARE TO: Ery-Tab
Amneal Pharmaceuticals has introduced erythromycin delayed-release tablets, the first generic of Arbor Pharmaceuticals' Ery-Tab. Erythromycin delayed-release tablets are indicated to treat infections caused by susceptible strains of designated microorganisms in a variety of diseases, including bronchitis, pertussis, and pneumonia. The drug works by stopping the growth of bacteria. The drug will be available in 250-, 333-, and 500-mg dosage strengths.
DOSAGE: Tablet
FOR MORE INFORMATION: amneal.com
Articles in this issue
about 6 years ago
Keep an Eye on Protein Kinase Inhibitorsabout 6 years ago
OTC Focus Case Studies: Painabout 6 years ago
What Are the Options for Treating Pain?about 6 years ago
Education, Law Enforcement, and Treatment Programs Are Keyabout 6 years ago
Dispensing Mistakes Can Happen to Pets, Tooabout 6 years ago
MRPs Are Both a Blessing and a Curseabout 6 years ago
Pharmacists Can Provide Optimal Migraine Treatmentsabout 6 years ago
Melrose Pharmacy Offers a Unique Feelabout 6 years ago
Topical Analgesics Provide Pain Reliefabout 6 years ago
Case Studies (September 2019)Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.















































































































































































































